Svitinib 50mg Capsule

About

Sunitinib is a multi-targeted receptor tyrosine kinase (RTK) inhibitor used in the treatment of various cancers, including renal cell carcinoma (RCC), gastrointestinal stromal tumor (GIST), and pancreatic neuroendocrine tumors (pNET). It works by inhibiting multiple RTKs involved in tumor growth, angiogenesis (formation of new blood vessels that feed tumors), and metastatic progression. Key targets include VEGFRs, PDGFRs, KIT, FLT3, and RET. By blocking these pathways, sunitinib effectively starves the tumor of its blood supply and directly inhibits cancer cell proliferation. Its broad spectrum of action makes it a valuable agent in managing advanced and metastatic forms of these challenging cancers, often improving progression-free survival and overall patient outcomes.

Uses

• Treatment of advanced renal cell carcinoma (RCC).
• Management of imatinib-resistant or intolerant gastrointestinal stromal tumor (GIST).
• Treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET).
• Used in specific types of advanced solid tumors.

Directions For Use

Take the capsules orally once daily, with or without food, as directed by your physician. It is typically taken on a specific schedule (e.g., 4 weeks on, 2 weeks off). Swallow whole with water.

Benefits

• Effective in treating advanced renal cell carcinoma.
• Provides a treatment option for imatinib-resistant GIST.
• Improves progression-free survival in pancreatic neuroendocrine tumors.
• Inhibits multiple pathways crucial for tumor growth and angiogenesis.
• Oral administration offers convenience for patients.
• Helps to control disease progression and tumor size.

Side Effects

• Fatigue
• Diarrhea
• Nausea and vomiting
• Stomatitis (mouth sores)
• Hand-foot syndrome (palmar-plantar erythrodysesthesia)
• Hypertension (high blood pressure)
• Thyroid dysfunction
• Myelosuppression (low blood counts)
• Skin discoloration
• Taste alteration
• Bleeding events
• Cardiac dysfunction (e.g., decreased ejection fraction)

Safety Measures

• Alcohol - Avoid or limit alcohol consumption as it may exacerbate gastrointestinal side effects and potentially increase the risk of liver toxicity.
• Pregnancy - Sunitinib is teratogenic and contraindicated in pregnancy. Women of childbearing potential must use effective contraception during treatment and for at least 3 weeks after the last dose.
• Breastfeeding - Breastfeeding is contraindicated during Sunitinib treatment and for at least 3 weeks after the last dose, due to potential harm to the infant.
• Liver - Use with caution in patients with hepatic impairment. Liver function should be monitored regularly, and dose adjustments may be necessary.
• Kidney - Use with caution in patients with severe renal impairment. Dosage adjustments may be required, and close monitoring is essential.
• Lung - Rarely, pulmonary embolism, interstitial lung disease, or pulmonary hypertension can occur. Report any new or worsening respiratory symptoms, chest pain, or shortness of breath.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.